CDER Shake-Up Includes Critical Path Office, New Safety Structure

Drug Industry Daily
KEYWORDS CDER / FDA
A A

The FDA's proposed realignment of the Center for Drug Evaluation and Research (CDER) calls for the creation of a new office dedicated to the agency's Critical Path Initiative, as well as a major restructuring of the center's drug safety activities.

To View This Article:

Login

Subscribe To Drug Industry Daily